Shannon Rourke Devens
Corporate Officer/Principal chez SURFACE ONCOLOGY, INC.
Postes actifs de Shannon Rourke Devens
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SURFACE ONCOLOGY, INC. | Corporate Officer/Principal | 15/12/2021 | - |
| Directeur Technique/Scientifique/R&D | 01/02/2018 | 15/12/2021 |
Historique de carrière de Shannon Rourke Devens
Anciens postes connus de Shannon Rourke Devens
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| INFINITY PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Formation de Shannon Rourke Devens
| Northeastern University | Graduate Degree |
| University of Colorado Boulder | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Graduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Shannon Rourke Devens
- Expérience